– $ 20.6 billion in sales, representing 1.3 %, Operational Progress 1.6 % * and Adjusted 3.7 % Operational Progress *
– $ 2.08 Improve 43.4 %; adjusted $ 2.58 EPS grew 22.9% *; Consists of Benefits Of Creating Advanced Sterilization Merchandise (ASP)
– Operational Gross sales Steerage Elevated On account of Enterprise Power; The vary of EPS control remained
Johnson & Johnson (NYSE: JNJ) as we speak introduced the outcomes of the second quarter of 2019. “We delivered strong second-quarter revenue growth and strong earnings performance, enabling us to make investments in innovation to accelerate our performance in every business,” says Chairman and CEO Alex Gorsky. “The progress of our pipelines will continue with the launch of latest products and various laws and approvals that may set us on the subsequent wave of transformation products and options. Am a proud Johnson Johnson & gifted colleagues, who proceed to offer vital advances in well being care of sufferers and shoppers to be able to improve life throughout the world.